1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis
June 20, 2023 08:00 ET | Timber Pharmaceuticals
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate Minimal Systemic Absorption of Isotretinoin - - Data to be Presented at the Society for...
Logo 1.png
Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
June 14, 2023 16:05 ET | Aeterna Zentaris Inc
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 14, 2023 08:45 ET | Palisade Bio, Inc.
Live webcast fireside chat on Thursday, June 22nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies...
ARIDIS_LOGO.png
Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update
June 08, 2023 16:05 ET | Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Promotes J.D. Finley to Chief Executive Officer
June 01, 2023 08:45 ET | Palisade Bio, Inc.
Carlsbad, CA, June 01, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic...
ARIDIS_LOGO.png
Aridis Pharmaceuticals Receives Nasdaq Notice on Late Filing of its Form 10-Q
May 25, 2023 16:05 ET | Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, announced today that it received a notice...
Logo.png
Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Addition to the Russell 2000® Index
May 25, 2023 08:01 ET | Ocean Biomedical, Inc.
Providence, RI, May 25, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) announced today that it is expected to be added to the Russell 2000® Index, effective after the U.S. market opens on...
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio’s LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts
May 24, 2023 08:45 ET | Palisade Bio, Inc.
Company approaching Phase 2 topline data readout for prevention of post-surgical abdominal adhesions Continued momentum with execution of ongoing dose optimization study with 25% enrollment...
1589917612572_5ec429193ef97e0004f1060c_logo.png
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2023 Financial Results
May 15, 2023 16:15 ET | Timber Pharmaceuticals
- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc....
Logo 1.png
Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
May 15, 2023 16:05 ET | Aeterna Zentaris Inc
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...